Bayer Announces $44M Investment in Myerstown Manufacturing Facility
Bayer celebrated a major milestone with the grand opening of a 70,000-square-foot expansion at its Myerstown, Pennsylvania manufacturing site, marking the completion of a $44 million investment announced in 2022. This state-of-the-art facility underscores Bayer’s long-standing commitment to delivering high-quality self-care products while fostering innovation, workforce development, and community engagement across North America.
The ribbon-cutting ceremony brought together Bayer leadership, employees, elected officials, and members of the Lebanon County community. It marked a significant moment in the evolution of Bayer’s Myerstown site, which has been operating for more than 75 years. Now, it stands as the largest manufacturing site within Bayer’s Consumer Health network globally—producing household names like Bayer® Aspirin, Aleve®, Claritin®, One A Day®, Alka-Seltzer Plus®, and Midol®.
“Our trusted brands have been helping people live healthier lives for generations,” said Dave Tomasi, President of Bayer’s Consumer Health division in North America. “The Myerstown annex will enable us to bring science-backed products to market with greater speed and reliability. This expansion strengthens our commitment to delivering safe, effective, and high-quality self-care solutions that our consumers and customers rely on.”
The new annex includes eight additional product packaging lines and advanced logistics systems, designed to increase efficiency and boost Bayer’s capacity to meet consumer demand. By modernizing its operations with integrated technologies and streamlined processes, the facility enhances Bayer’s ability to deliver science-driven health products with speed, precision, and consistency.
But Bayer’s investment in Myerstown goes beyond infrastructure and technology. The expansion represents a broader vision for sustainable growth that includes developing local talent and supporting the region’s economic vitality. Bayer is investing in workforce development initiatives to equip employees with the digital and technical skills needed in today’s evolving manufacturing landscape.
“We recognize that the key to sustainable growth lies in our people,” said Divakar Amin, Vice President & Site Manager of Bayer’s Myerstown facility. “That’s why we are focused on enabling our workforce to adapt and thrive with the latest technologies. We’re proud to contribute to the local economy and to support a workforce that includes many members of the Myerstown community.”
As part of its educational outreach, Bayer plans to collaborate with local high schools, welcoming educators to tour the facility and gain insights into modern manufacturing. These efforts aim to bridge classroom learning with real-world application, inspiring the next generation of skilled workers and helping educators bring industry-aligned knowledge back to their schools.
Bayer’s Myerstown expansion reinforces the company’s broader mission to improve lives through health and nutrition. This includes ensuring equitable access to essential self-care products, promoting science-based innovation, and empowering communities with tools to take control of their health.
“Our commitment to credible science and consumer advocacy drives our mission—Health for all, Hunger for none,” said Michael Sullivan, Senior Vice President of Product Supply for Bayer’s Consumer Health division in North America. “This investment paves the way for a healthier future, ensuring more people have access to the trusted products they need to support their well-being.”
About Bayer
Bayer is a global life sciences company with core competencies in healthcare and nutrition. Guided by its mission—Health for all, Hunger for none—Bayer delivers innovative products and services designed to meet the growing health and nutrition needs of a changing world. The company is committed to sustainable development, driving forward solutions that benefit people, communities, and the planet.
As of fiscal year 2024, Bayer employed around 93,000 people worldwide and generated sales of €46.6 billion. The company invested €6.2 billion in research and development, demonstrating its continued focus on innovation and long-term growth. The Bayer name is recognized globally as a symbol of trust, quality, and reliability.
Through strategic investments like the Myerstown expansion, Bayer continues to play a leading role in strengthening U.S. manufacturing, supporting local economies, and delivering science-backed health solutions that empower consumers to live better, healthier lives.
